Semaglutide
SM10 · 10mg · 2026-08-16 · N/A
COA PDF ↗
SM10Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
Semaglutide
Weight management and weight-loss maintenance
Semaglutide specifications and reference prices. Select a specification to add it to your cart.
10mg/vial x 10vials
Reference priceUS$90.91
For laboratory research only. Not for human or veterinary use.
COA 检测报告 / Reports
Compare all specifications & reference prices
| SKU | Specification / pack | Reference price (USD) |
|---|---|---|
| SM2 | 2mg/vial x 10vials | US$26.47 |
| SM5 | 5mg/vial x 10vials | US$60.61 |
| SM10 | 10mg/vial x 10vials | US$90.91 |
| SM15 | 15mg/vial x 10vials | US$115.15 |
| SM20 | 20mg/vial x 10vials | US$145.45 |
| SM30 | 30mg/vial x 10vials | US$200 |
| SM40 | 40mg/vial x 10vials | US$266.67 |
| SM50 | 50mg/vial x 10vials | US$333.33 |
Temporarily sold-out specifications can still be added to an inquiry to ask about restocking. An inquiry is not an order or an agreed price.
DOCUMENTATION / SM10
Semaglutide — supplied COA and inquiry notes
The Semaglutide catalog group currently lists 8 specifications. Use the selector and specification table above to compare SKUs and reference prices. The linked report identifies sample SM10; its sample code is not a separate specification selection.
- Report sample code
- SM10
- Reported date
- 2026-08-16
- Sample purity (HPLC-UV)
- 99.79%
- Sample net content
- 11.30 mg
- Lot / batch field
- N/A
- Endotoxin result
- N/A
These values describe the supplied test sample only.
When inquiring about Semaglutide, include the exact SKU, pack quantity and destination. Ask for stock and batch-document confirmation. Temporarily sold-out specifications can still be queried; the cart is not a confirmed order.
For laboratory research only. Not for human or veterinary use. The supplied report footnotes also exclude diagnostic, therapeutic and clinical applications.
Explore GLP-1 & Metabolic Research ↗ · View all products
RESEARCH FOCUS
Main Uses & FAQs
This page organizes directly related information on Semaglutide regarding weight management and weight loss maintenance. First, look at research questions and findings, then verify the population or species, study formulations, and scope of interpretation.
Main TopicsWeight Management · Weight Loss Maintenance
USAGE REFERENCE
Semaglutide · Usage reference (for research purposes)
The following presents common research-context references for reconstitution, storage, dosage and cycles. The following presents common references in research settings. This page does not constitute advice for use in humans or animals.
🧪Reconstitution
- Suggested Diluent
- Bacteriostatic Water (containing 0.9% benzyl alcohol); some peptides may use sterile water or acetic acid to aid dissolution. See the individual product descriptions.
- Diluent Volume
- Slowly introduce the diluent along the vial wall until the lyophilized powder is covered. A common example is 5 mg reconstituted with 2 mL of bacteriostatic water, yielding approximately 2.5 mg/mL. Referenced reconstitution volumes are approximately 1–2.5 mL, with 2 mL commonly used. It is suggested to select and record a fixed volume based on the COA supplied with the purchase.
- Handling Notes
- Introduce the diluent slowly along the vial wall rather than directly onto the lyophilized powder. Leave it for 60–90 seconds to dissolve naturally; do not shake vigorously.
💾Storage
- Unreconstituted Lyophilized Powder
- Refrigerate at 2–8°C, protected from light; avoid repeated freeze–thaw cycles.
- After Reconstitution
- Refrigerate at 2–8°C; a common recommendation is touse within 28 days; do not freeze.
- Transport
- For short periods, use insulated packaging with ice packs; avoid high temperatures and direct light.
📏Dosage Reference (Research)
| Purpose / Setting | Common Reference |
|---|---|
| Initiation/Titration | Common studies start from low dose and gradually increase; subcutaneous injection according to purchased dosage form and device scale |
| Administration Route | Subcutaneous Injection (Rotation: Abdomen/Thigh/Upper Arm) |
| Frequency | Once a week (injection type) |
🔁Cycle
Fixed day of the week, rotating injection sites on abdomen/thigh/upper arm, with at least 1–2 inch intervals each time.
View the Complete Usage Guide Library →Note: The above describes common research-context references, rather than clinical recommendations. Refer to the batch COA and research protocol. For research use only; not for human or animal use.
References
Read the Full Research Review ↗Research SummaryKey Findings
What research findings exist for Semaglutide in weight management and weight loss maintenance?
44 weeks of weight loss reached the preset equivalence standard compared with reference semaglutide. Additionally, a study report showed: the semaglutide group had an average weight loss of 15.2%, placebo 2.6%, supporting continued weight loss over two years.[1] ↗ [2] ↗
Before ReadingStudy populations, species, formulations and delivery conditions each have a defined scope. Research on an ingredient does not establish that this site's product batches have been validated for efficacy in humans or veterinary use.
Human Study2026REF. 01
What does the study’s weight loss equivalence comparison of preparations indicate?
Research Findings
44 weeks of weight loss reached the preset equivalence standard compared with reference semaglutide.[1] ↗
Study Design
Human Randomization Phase III; Obese adults in China
Scope & Limitations
Studies HD1916 and Wegovy, and cannot conclude that Ventro formulation is equivalent on this basis.
View the Article Title and Full Citation＋
Efficacy and Safety of Chemically Synthesized Semaglutide Injection (HD1916) for the Treatment of Obesity: A Multicenter, Randomized, Phase III Trial.
Diabetes, obesity & metabolism · Volume and Issue Year 2026
First published 2026-10-07 · PMID 42839752
DOI 10.1111/dom.71354
Human Study2022REF. 02
What was observed during the two-year follow-up?
Research Findings
The Semaglutide group showed an average weight loss of 15.2%, compared to 2.6% with placebo, supporting sustained weight loss over two years.[2] ↗
Study Design
STEP5; 304 adults with obesity or overweight without diabetes; 104-week randomized controlled trial
Scope & Limitations
Both groups received behavioral interventions; mainly white women; gastrointestinal adverse events were more common. The formulations in the papers are different from research commodities.
View the Article Title and Full Citation＋
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
Nature medicine · Volume/Issue Year 2022
First published 2022-10-01 · PMID 36216945
DOI 10.1038/s41591-022-02026-4
Human Study2021 · Historical basic researchREF. 03
What were the findings of the 68-week weight management study?
Research Findings
In the semaglutide group, the average body weight decreased by 14.9%, and in the placebo group by 2.4%, directly supporting weight management research.[3] ↗
Study Design
1,961 overweight or obese adults without diabetes; STEP1 randomized trial, 68 weeks
Scope & Limitations
Both groups had lifestyle interventions; basic research in 2021, gastrointestinal reactions were common; study formulations do not represent catalog products.
View the Article Title and Full Citation＋
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
The New England Journal of Medicine · Volume, Issue, Year 2021
First published 2021-02-10 · PMID 33567185
DOI 10.1056/NEJMoa2032183
Currently, 3 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.
GO DEEPER
↗What Questions Do These Studies Address?
Compare study populations, findings and scope.
Semaglutide · Frequently Asked Questions.
What research findings exist for Semaglutide in weight management and weight loss maintenance?＋
44 weeks of weight loss reached the preset equivalence standard compared with reference semaglutide. Additionally, a study report showed: the semaglutide group had an average weight loss of 15.2%, placebo 2.6%, supporting continued weight loss over two years.[1] ↗ [2] ↗
How long was the long-term weight management study?＋
STEP5 extended the follow-up to 104 weeks. The semaglutide group had an average weight loss of 15.2%, compared to 2.6% in the placebo group. These are two-year results and should not be directly ranked against trials of other durations.[2] ↗
Semaglutide—these conclusions apply to which study populations?＋
Randomized phase III human study in Chinese adults with obesity; STEP5 included 304 adults with obesity or overweight without diabetes in a 104-week randomized controlled trial; STEP1 included 1961 adults with overweight or obesity without diabetes in a 68-week randomized trial. The formulations studied were HD1916 and Wegovy; these findings do not establish equivalence of Ventro's formulation.[1] ↗ [2] ↗ [3] ↗
VENTRO PEPTIDES & BIOTECH · RESEARCH PRODUCT RETAIL
Research peptides. Shop by product.
Compare specifications, reference prices and COA reports. Add products to your cart to request a quote.
QUALITY DOCUMENTSCOA BY PRODUCTGLOBAL DELIVERYTECHNICAL SUPPORT
01 / CATALOG
Browse products
Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
Semaglutide
10mg/vial x 10vials
US$90.91
Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
Tirzepatide
20mg/vial x 10vials
US$160.61
Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
Retatrutide
10mg/vial x 10vials
US$109.09
Images are illustrative. Actual specifications are as selected and confirmed in writing.
Repair & Recovery Research
BPC157
10mg/vial x 10vials
US$133.33
Images are illustrative. Actual specifications are as selected and confirmed in writing.
Longevity & Mitochondrial Research
MOTS-C
20mg/vial x 10vials
US$257.58
Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
Liraglutide
10mg*10vials
US$164.71
Images are illustrative. Actual specifications are as selected and confirmed in writing.
Growth Hormone & IGF-1
IGF-lr3
1mg/vial x 10vials
US$505.8802 / DISCOVER
Browse categories
01 / 04
03 / ABOUT VENTRO
Reliable peptide supply, built for long-term partnerships.
Ventro supports research product retail purchases with clear pack specifications, available quality documents, and responsive international support.
- High-purity peptides
- Available COA reports
- COA & quality documentation
- Flexible small-quantity purchases
- Reliable global fulfillment
- Research product retail support
04 / QUALITY SYSTEM
Quality without compromise
Browse the available COA reports by product. Confirm documentation for your order with our team.
Controlled quality workflowRaw material to final release
Responsive global supportProduct matching and technical support
RESEARCH PRODUCT INQUIRY
Submit a product inquiry
Tell us the product, specification, and expected quantity. Our team will respond with pricing and available documents.